You can buy Adakras at the lowest price at Nextgen.ooo online pharmacy. Adagrasib is an orally administered small molecule KRAS inhibitor developed by Mirati Therapeutics. KRAS mutations are very common in cancer, accounting for approximately 85% of all RAS family mutations. However, developing KRAS inhibitors has proven challenging due to their high affinity for guanosine triphosphate and guanosine diphosphate, and the lack of a clear binding pocket. Adagrasib targets KRASG12C, one of the most common KRAS mutations, at cysteine ​​12 residue and inhibits KRAS-dependent signaling. In a Phase I/IB clinical trial involving patients with advanced solid tumors harboring a KRASG12C mutation, adagrasib demonstrated antitumor activity. A phase II study from the same study showed that in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC), adagrasib was effective without new safety signals.
 
In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRASG12C-positive NSCLC. In December 2022, the FDA granted adagrasib accelerated approval for the treatment of locally advanced or metastatic KRASG12C-mutated NSCLC who have received at least one prior systemic therapy. Adagrasib joins sotorasib as the other KRASG12C inhibitor approved by the FDA.